{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:08:06Z","timestamp":1780931286767,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Retinopathy of prematurity (ROP) is a condition affecting the underdeveloped retinas of premature infants, particularly those exposed to oxygen therapy. While mild cases often resolve on their own, severe ROP can cause retinal detachment, vision loss, or blindness. ROP remains a challenge due to the need to balance treatment benefits and risks. Anti-Vascular Endothelial Growth Factor (VEGF) therapy has emerged as a promising, minimally invasive treatment for significant ROP, offering shorter administration time, ease of use, and reduced need for surgery or anesthesia. This treatment is increasingly initiated in NICUs following routine screening. However, uncertainties remain regarding the best Anti-VEGF drug, dosing strategies, potential systemic side effects, and long-term neurodevelopmental impacts. Under the guidance of an ophthalmologist, Anti-VEGF agents are the preferred first-line therapy in many cases, whereas laser therapy remains the gold standard for others. Neonatologists and paediatricians must be well-versed in ROP screening, risk factors, and treatment approaches to ensure optimal outcomes for preterm infants.<\/jats:p>","DOI":"10.1093\/pch\/pxag030","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:47:48Z","timestamp":1774702068000},"page":"326-332","source":"Crossref","is-referenced-by-count":0,"title":["Retinopathy of prematurity: Anti vascular endothelial growth factor (Anti-VEGF) or laser photocoagulation?"],"prefix":"10.1093","volume":"31","author":[{"given":"Arijit","family":"Lodha","sequence":"first","affiliation":[{"name":"Faculty of Dentistry & Medicine, University of Alberta , Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4809-0765","authenticated-orcid":false,"given":"Amelie","family":"Stritzke","sequence":"additional","affiliation":[{"name":"Section of Neonatology, Department of Pediatrics, Cumming School of Medicine, University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dotchin","sequence":"additional","affiliation":[{"name":"Section of Ophthalmology, Department of Surgery, Cumming School pf Medicine, University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"11","key":"2026060810564675600_pxag030-B1","doi-asserted-by":"publisher","first-page":"e73286","DOI":"10.7759\/cureus.73286","article-title":"Recurrence of retinopathy of prematurity following anti-vascular endothelial growth factor (Anti-VEGF) therapy: A systematic review and meta-analysis","volume":"16","author":"Dablouk","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"2026060810564675600_pxag030-B2","doi-asserted-by":"publisher","first-page":"CD009734","DOI":"10.1002\/14651858.CD009734.pub3","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2026060810564675600_pxag030-B3","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"issue":"7","key":"2026060810564675600_pxag030-B4","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1542\/neo.2-7-e153","article-title":"Retinopathy of prematurity: History, classification, and pathophysiology","volume":"2","author":"Phelps","year":"2001","journal-title":"Neoreviews"},{"issue":"2","key":"2026060810564675600_pxag030-B5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/pch\/21.2.101","article-title":"Retinopathy of prematurity: An update on screening and management","volume":"21","author":"Jefferies","year":"2016","journal-title":"Paediatr Child Health"},{"key":"2026060810564675600_pxag030-B6","author":"Canadian Neonatal Network"},{"issue":"11","key":"2026060810564675600_pxag030-B7","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1001\/archopht.120.11.1470","article-title":"Evidence-based screening criteria for retinopathy of prematurity: Natural history data from the CRYO-ROP and LIGHT-ROP studies","volume":"120","author":"Reynolds","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"2026060810564675600_pxag030-B8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7554\/eLife.80550","article-title":"Retinopathy of prematurity: Metabolic risk factors","volume":"11","author":"Fu","year":"2022","journal-title":"Elife"},{"issue":"3","key":"2026060810564675600_pxag030-B9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.sjopt.2012.05.006","article-title":"Long term visual outcomes in laser treated threshold retinopathy of prematurity in Central Saudi Arabia","volume":"26","author":"Al-Otaibi","year":"2012","journal-title":"Saudi J Ophthalmol"},{"issue":"2","key":"2026060810564675600_pxag030-B10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/s0161-6420(99)00042-1","article-title":"A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity","volume":"107","author":"Banach","year":"2000","journal-title":"Ophthalmology"},{"issue":"12","key":"2026060810564675600_pxag030-B11","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"2026060810564675600_pxag030-B12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jcjo.2013.12.014","article-title":"Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity","volume":"49","author":"Ehmann","year":"2014","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"2026060810564675600_pxag030-B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1067\/mpa.2002.121452","article-title":"Clinical outcome of confluent laser photoablation for retinopathy of prematurity","volume":"6","author":"Fallaha","year":"2002","journal-title":"J AAPOS"},{"issue":"2","key":"2026060810564675600_pxag030-B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3928\/01913913-20100308-05","article-title":"Confluent laser photocoagulation for the treatment of retinopathy of prematurity","volume":"47","author":"Gonzalez","year":"2010","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"5","key":"2026060810564675600_pxag030-B15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/ceo.12280","article-title":"Prevalence and outcomes of laser treatment of aggressive posterior retinopathy of prematurity","volume":"42","author":"Gunn","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"2026060810564675600_pxag030-B16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3980\/j.issn.2222-3959.2013.02.23","article-title":"Treatment of retinopathy of prematurity: A review of conventional and promising new therapeutic options","volume":"6","author":"Mutlu","year":"2013","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"2026060810564675600_pxag030-B17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/archopht.123.5.621","article-title":"Near confluent laser photocoagulation for the treatment of threshold retinopathy of prematurity","volume":"123","author":"Rezai","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"2026060810564675600_pxag030-B18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.22608\/APO.201837","article-title":"Anti-VEGF for ROP and pediatric retinal diseases","volume":"7","author":"Wu","year":"2018","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"12","key":"2026060810564675600_pxag030-B19","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41372-019-0503-x","article-title":"Oral propranolol in prevention of severe retinopathy of prematurity: A systematic review and meta-analysis","volume":"39","author":"Stritzke","year":"2019","journal-title":"J Perinatol"},{"issue":"1","key":"2026060810564675600_pxag030-B20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/aos.17541","article-title":"Impact of anti-VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta-analysis","volume":"104","author":"Wang","year":"2026","journal-title":"Acta Ophthalmol"},{"key":"2026060810564675600_pxag030-B21","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"6","key":"2026060810564675600_pxag030-B22","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of Vascular Endothelial Growth Factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"2026060810564675600_pxag030-B23","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1097\/iae.0000000000003196","article-title":"FACTORS associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina"},{"issue":"10208","key":"2026060810564675600_pxag030-B24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"2026060810564675600_pxag030-B25","doi-asserted-by":"publisher","first-page":"884608","DOI":"10.3389\/fmed.2022.884608","article-title":"Intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity: A systematic review and meta-analysis","volume":"9","author":"Taher","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"2026060810564675600_pxag030-B26","doi-asserted-by":"publisher","first-page":"191.e1","DOI":"10.1016\/j.jaapos.2022.05.006","article-title":"A comparison of primary laser versus laser after anti-vascular endothelial growth factor for type 1 retinopathy of prematurity","volume":"26","author":"Lajoie","year":"2022","journal-title":"J AAPOS"},{"issue":"6","key":"2026060810564675600_pxag030-B27","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"2026060810564675600_pxag030-B28","author":"The Royal College of Ophthalmologists. Treating Retinopathy of Prematurity in the UK. 2022. p. 1\u201389"},{"issue":"7","key":"2026060810564675600_pxag030-B29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3928\/23258160-20200702-05","article-title":"SAFER-ROP: Updated protocol for anti-VEGF injections for retinopathy of prematurity","volume":"51","author":"Beck","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"5","key":"2026060810564675600_pxag030-B30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: A report by the American academy of ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"issue":"2","key":"2026060810564675600_pxag030-B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"issue":"6","key":"2026060810564675600_pxag030-B32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41372-020-00884-9","article-title":"Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: A systematic review and meta-analysis","volume":"41","author":"Kaushal","year":"2021","journal-title":"J Perinatol"},{"issue":"1","key":"2026060810564675600_pxag030-B33","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"2026060810564675600_pxag030-B34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: Fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"}],"container-title":["Paediatrics &amp; Child Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pch\/article-pdf\/31\/4\/326\/68179693\/pxag030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pch\/article-pdf\/31\/4\/326\/68179693\/pxag030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:56:56Z","timestamp":1780930616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pch\/article\/31\/4\/326\/8664104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,28]]},"published-print":{"date-parts":[[2026,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/pch\/pxag030","relation":{},"ISSN":["1205-7088","1918-1485"],"issn-type":[{"value":"1205-7088","type":"print"},{"value":"1918-1485","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,28]]}}}